Clinical Trials · NCT01538966

Acromegaly Combination Treatment Study

TerminatedN/AOctreotide (Prohibited)Lanreotide (Prohibited)
Phase
N/A
Recruitment status
Terminated
Sponsor
Cedars-Sinai Medical Center
Enrollment
76
Start date
Mar 2012
Locations
1 site, United States
Primary endpoint
Cost Effectiveness
View Octreotide compound reference